COMMUNIQUÉS West-GlobeNewswire

-
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
25/03/2024 -
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
25/03/2024 -
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
25/03/2024 -
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
25/03/2024 -
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
25/03/2024 -
Starton Therapeutics to Present at Upcoming MedInvest and Needham Conferences
25/03/2024 -
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
25/03/2024 -
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
25/03/2024 -
One World Products, Inc. Secures Exclusive Rights With Procepack for State-of-the-Art PreRoll-Er Equipment in Colombia
25/03/2024 -
Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection
25/03/2024 -
GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare
25/03/2024 -
Olink reports fourth quarter and full year 2023 financial results
25/03/2024 -
Olink publishes 2023 annual report
25/03/2024 -
Novo Nordisk A/S - share repurchase programme
25/03/2024 -
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
25/03/2024 -
Nkarta Announces Pricing of $240 Million Underwritten Offering
25/03/2024 -
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
25/03/2024 -
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
25/03/2024 -
Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635
25/03/2024
Pages